{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:26:56Z","timestamp":1791581216182,"version":"4.3.4"},"reference-count":150,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Human cytomegalovirus (HCMV) is a herpesvirus capable of establishing a lifelong persistence in the host through a chronic state of infection and remains an essential global concern due to its distinct life cycle, mutations, and latency. It represents a life-threatening pathogen for immunocompromised patients, such as solid organ transplanted patients, HIV-positive individuals, and hematopoietic stem cell recipients. Multiple antiviral approaches are currently available and administered in order to prevent or manage viral infections in the early stages. However, limitations due to side effects and the onset of antidrug resistance are a hurdle to their efficacy, especially for long-term therapies. Novel antiviral molecules, together with innovative approaches (e.g., genetic editing and RNA interference) are currently in study, with promising results performed in vitro and in vivo. Since HCMV is a virus able to establish latent infection, with a consequential risk of reactivation, infection management could benefit from preventive treatment for critical patients, such as immunocompromised individuals and seronegative pregnant women. This review will provide an overview of conventional antiviral clinical approaches and their mechanisms of action. Additionally, an overview of proposed and developing new molecules is provided, including nucleic-acid-based therapies and immune-mediated approaches.<\/jats:p>","DOI":"10.3390\/microorganisms11102372","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T03:44:42Z","timestamp":1695354282000},"page":"2372","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Antiviral Approach to Cytomegalovirus Infection: An Overview of Conventional and Novel Strategies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-5729","authenticated-orcid":false,"given":"Paolo","family":"Bottino","sequence":"first","affiliation":[{"name":"Microbiology and Virology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pastrone","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8101-4196","authenticated-orcid":false,"given":"Antonio","family":"Curtoni","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bondi","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sidoti","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Zanotto","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Cavallo","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Solidoro","sequence":"additional","affiliation":[{"name":"Pneumology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-4553","authenticated-orcid":false,"given":"Cristina","family":"Costa","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2174\/187152611797636703","article-title":"Diagnosis of Cytomegalovirus Infections","volume":"11","author":"Ross","year":"2011","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Van Damme, E., and Van Loock, M. (2014). Functional annotation of human cytomegalovirus gene products: An update. Front. Microbiol., 5.","DOI":"10.3389\/fmicb.2014.00218"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ye, L., Qian, Y., Yu, W., Guo, G., Wang, H., and Xue, X. (2020). Functional Profile of Human Cytomegalovirus Genes and Their Associated Diseases: A Review. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.02104"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/jmbi.1999.3344","article-title":"Cryomicroscopy of human cytomegalovirus virions reveals more densely packed genomic DNA than in herpes simplex virus type 1","volume":"295","author":"Bhella","year":"2000","journal-title":"J. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"eaam6892","DOI":"10.1126\/science.aam6892","article-title":"Atomic structure of the human cytomegalovirus capsid with its securing tegument layer of pp150 HHS Public Access","volume":"356","author":"Yu","year":"2017","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/jsbi.1998.4055","article-title":"Structure of the human cytomegalovirus B capsid by electron cryomicroscopy and image reconstruction","volume":"124","author":"Butcher","year":"1998","journal-title":"J. Struct. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1743-422X-9-22","article-title":"Human cytomegalovirus tegument proteins (pp65, pp71, pp150, pp28)","volume":"9","author":"Tomtishen","year":"2012","journal-title":"Virol. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1128\/MMBR.00040-07","article-title":"Tegument Proteins of Human Cytomegalovirus","volume":"72","author":"Kalejta","year":"2008","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Garoff, H., Hewson, R., and Opstelten, D.-J.E. (1998). Virus Maturation by Budding. Microbiol. Mol. Biol. Rev., 62.","DOI":"10.1128\/MMBR.62.4.1171-1190.1998"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1128\/JVI.77.5.3191-3203.2003","article-title":"Envelopment of Human Cytomegalovirus Occurs by Budding into Golgi-Derived Vacuole Compartments Positive for gB, Rab 3, Trans-Golgi Network 46, and Mannosidase II","volume":"77","author":"Hultenby","year":"2003","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Foglierini, M., Marcandalli, J., and Perez, L. (2019). HCMV envelope glycoprotein diversity demystified. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01005"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/14789450.2014.971116","article-title":"The life cycle and pathogenesis of human cytomegalovirus infection: Lessons from proteomics","volume":"11","author":"Cristea","year":"2014","journal-title":"Expert Rev. Proteom."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gerna, G., Kabanova, A., and Lilleri, D. (2019). Human cytomegalovirus cell tropism and host cell receptors. Vaccines, 7.","DOI":"10.3390\/vaccines7030070"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1128\/JVI.00384-11","article-title":"The Human Cytomegalovirus Gene Products Essential for Late Viral Gene Expression Assemble into Prereplication Complexes before Viral DNA Replication","volume":"85","author":"Isomura","year":"2011","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1128\/JVI.75.1.26-35.2001","article-title":"Dominance of Virus over Host Factors in Cross-Species Activation of Human Cytomegalovirus Early Gene Expression","volume":"75","author":"Ruchti","year":"2001","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Adamson, C.S., and Nevels, M.M. (2020). Bright and early: Inhibiting human cytomegalovirus by targeting major immediate-early gene expression or protein function. Viruses, 12.","DOI":"10.3390\/v12010110"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/JVI.02983-13","article-title":"Transcription of True Late (\u03b32) Cytomegalovirus Genes Requires UL92 Function That Is Conserved among Beta- and Gammaherpesviruses","volume":"88","author":"Omoto","year":"2014","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110653","DOI":"10.1016\/j.celrep.2022.110653","article-title":"Temporal dynamics of HCMV gene expression in lytic and latent infections","volume":"39","author":"Rozman","year":"2022","journal-title":"Cell Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: From bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/313761","article-title":"Human Cytomegalovirus Latency: Targeting Differences in the Latently Infected Cell with a View to Clearing Latent Infection","volume":"2014","author":"Poole","year":"2014","journal-title":"New J. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Fowler, K., Mucha, J., Neumann, M., Lewandowski, W., Kaczanowska, M., Grys, M., Schmidt, E., Natenshon, A., Talarico, C., and Buck, P.O. (2022). A systematic literature review of the global seroprevalence of cytomegalovirus: Possible implications for treatment, screening, and vaccine development. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-13971-7"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fped.2020.00013","article-title":"Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and Management From a Panel of European Experts","volume":"8","author":"Lazzarotto","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev. Med. Virol."},{"key":"ref_26","unstructured":"Thomasini, R.L. (2019). Human Herpesvirus Infection, IntechOpen."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1824-7288-37-6","article-title":"Breastfeeding and transmission of cytomegalovirus to preterm infants. Case report and kinetic of CMV-DNA in breast milk","volume":"37","author":"Chiavarini","year":"2011","journal-title":"Ital. J. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/rmv.659","article-title":"Cytomegalovirus seroconversion rates and risk factors: Implications for congenital CMV","volume":"20","author":"Hyde","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rubinacci, V., Fumagalli, M., Meraviglia, G., Gianolio, L., Sala, A., Stracuzzi, M., Dighera, A., Zuccotti, G.V., and Giacomet, V. (2022). Congenital CMV, Lights and Shadows on Its Management: The Experience of a Reference Center in Northern Italy. Children, 9.","DOI":"10.3390\/children9050655"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20926","DOI":"10.1038\/s41598-022-25451-4","article-title":"Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: A retrospective study","volume":"12","author":"Shimada","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"Cytomegalovirus in solid organ transplant recipients","volume":"9","author":"Humar","year":"2009","journal-title":"Am. J. Transplant"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1753495X14552719","article-title":"Congenital cytomegalovirus infection: Clinical presentation, epidemiology, diagnosis and prevention","volume":"7","author":"Hamilton","year":"2014","journal-title":"Obstet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1590\/S1679-45082015RW3175","article-title":"Cytomegalovirus infection in renal transplantation: Clinical aspects, management and the perspectives","volume":"13","year":"2015","journal-title":"Einstein"},{"key":"ref_35","first-page":"8","article-title":"Indirect effects of CMV in the solid organ transplant patient","volume":"1","author":"Paya","year":"1999","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Diena, D., Allesina, A., Fop, F., Mella, A., Cavallo, R., Costa, C., Dolla, C., Gallo, E., De Rosa, F.G., and Lavacca, A. (2023). Relationship between Cytomegalovirus Viremia and Long-Term Outcomes in Kidney Transplant Recipients with Different Donor Ages. Microorganisms, 11.","DOI":"10.3390\/microorganisms11020458"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1093\/infdis\/jiz601","article-title":"Clinical Diagnostic Testing for Human Cytomegalovirus Infections","volume":"221","author":"Razonable","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12985-022-01913-z","article-title":"Detection of cytomegalovirus (CMV) by digital PCR in stool samples for the non-invasive diagnosis of CMV gastroenteritis","volume":"19","author":"Gu","year":"2022","journal-title":"Virol. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1128\/JCM.01039-11","article-title":"Diagnostic consequences of cytomegalovirus glycoprotein B polymorphisms","volume":"49","author":"Novak","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"10841","DOI":"10.1128\/JVI.76.21.10841-10848.2002","article-title":"The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates","volume":"76","author":"Rasmussen","year":"2002","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1128\/JCM.02473-07","article-title":"Exon 4 of the human cytomegalovirus (CMV) major immediate-early gene as a target for CMV real-time PCR","volume":"46","author":"Ducroux","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/infdis\/163.6.1229","article-title":"Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes","volume":"163","author":"Chou","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.bbmt.2018.03.005","article-title":"Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients","volume":"24","author":"Lazzarotto","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Rzepka, M., Depka, D., Gospodarek-Komkowska, E., and Bogiel, T. (2022). Whole Blood versus Plasma Samples-How Does the Type of Specimen Collected for Testing Affect the Monitoring of Cytomegalovirus Viremia?. Pathogens, 11.","DOI":"10.3390\/pathogens11111384"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rzepka, M., Depka, D., Gospodarek-Komkowska, E., and Bogiel, T. (2023). Diagnostic Value of Whole-Blood and Plasma Samples in Epstein-Barr Virus Infections. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030476"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e13149","DOI":"10.1111\/ctr.13149","article-title":"Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of immunocompromised patients with CMV pneumonia","volume":"32","author":"Beam","year":"2018","journal-title":"Clin. Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"114685","DOI":"10.1016\/j.jviromet.2023.114685","article-title":"Efficiency of CMV serodiagnosis during pregnancy in daily laboratory routine","volume":"314","author":"Flindt","year":"2023","journal-title":"J. Virol. Methods"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2017","DOI":"10.1002\/rmv.2017","article-title":"Going beyond serology for stratifying the risk of CMV infection in transplant recipients","volume":"29","author":"Navarro","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/CVI.05633-11","article-title":"Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8 + T-cell response in allogeneic stem cell transplant recipients","volume":"19","author":"Clari","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lee, H., Park, K.H., Ryu, J.H., Choi, A.R., Yu, J.H., Lim, J., Han, K., Kim, S., Yang, C.W., and Chung, B.H. (2017). Cytomegalovirus (CMV) immune monitoring with ELISPOTand QuantiFERON-CMV assay in seropositive kidney transplant recipients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189488"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"392.e1","DOI":"10.1016\/j.jtct.2023.03.018","article-title":"Immunologic Monitoring after Allogeneic Stem Cell Transplantation: T-SPOT.CMV and QuantiFERON-CMV, Are They the Same?","volume":"29","author":"Callens","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jcv.2014.09.015","article-title":"Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patien","volume":"61","author":"Costa","year":"2014","journal-title":"J. Clin. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.transproceed.2011.03.024","article-title":"Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients","volume":"43","author":"Costa","year":"2011","journal-title":"Transplant. Proc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","volume":"37","author":"Plotkin","year":"2019","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Scarpini, S., Morigi, F., Betti, L., Dondi, A., Biagi, C., and Lanari, M. (2021). Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice. Vaccines, 9.","DOI":"10.3390\/vaccines9060551"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Rozhnova, G., Kretzschmar, M.E., van der Klis, F., van Baarle, D., Korndewal, M., Vossen, A.C., and van Boven, M. (2020). Short- and long-term impact of vaccination against cytomegalovirus: A modeling study. BMC Med., 18.","DOI":"10.1186\/s12916-020-01629-3"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chen, S.J., Wang, S.C., and Chen, Y.C. (2019). Antiviral agents as therapeutic strategies against cytomegalovirus infections. Viruses, 12.","DOI":"10.3390\/v12010021"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Panda, K., Parashar, D., and Viswanathan, R. (2023). An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection. Viruses, 15.","DOI":"10.3390\/v15061358"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e12773","DOI":"10.1111\/tid.12773","article-title":"Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey","volume":"19","author":"Navarro","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"953210","DOI":"10.3389\/fimmu.2022.953210","article-title":"Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?: A systematic review and meta-analysis","volume":"13","author":"Yadav","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"104211","DOI":"10.1016\/j.jcv.2019.104211","article-title":"CMV infection management in transplant patients in Italy","volume":"123","author":"Grossi","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients with Seropositive Donors: A Randomized Clinical Trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/00003495-199448030-00009","article-title":"Ganciclovir. An update of its therapeutic use in cytomegalovirus infection","volume":"48","author":"Markham","year":"1994","journal-title":"Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","article-title":"Ganciclovir","volume":"335","author":"Crumpacker","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Galar, A., Valerio, M., Catal\u00e1n, P., Garc\u00eda-Gonz\u00e1lez, X., Burillo, A., Fern\u00e1ndez-Cruz, A., Zatar\u00e1in, E., Sousa-Casasnovas, I., Anaya, F., and Rodr\u00edguez-Ferrero, M.L. (2021). Valganciclovir\u2014Ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship. Antibiotics, 10.","DOI":"10.3390\/antibiotics10010077"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"89","author":"Kotton","year":"2010","journal-title":"Transplantation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e13666","DOI":"10.1111\/ctr.13666","article-title":"Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies","volume":"33","author":"Girmenia","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/bs.seda.2022.09.006","article-title":"Antiviral drugs","volume":"Volume 44","author":"Samuel","year":"2022","journal-title":"Side Effects of Drugs Annual"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"ofz480","DOI":"10.1093\/ofid\/ofz480","article-title":"Analysis of Ganciclovir-Resistant Cytomegalovirus Infection Caused by the UL97 Gene Mutation in Codons 460 and 520 in Pediatric Patients: A Case Series","volume":"6","author":"Boonsathorn","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_71","unstructured":"Das, D., and Hong, J. (2019). Viral Polymerases, Academic Press."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199652020-00006","article-title":"Cidofovir","volume":"52","author":"Lea","year":"1996","journal-title":"Drugs"},{"key":"ref_73","unstructured":"Paintsil, E., and Cheng, Y.C. (2009). Encyclopedia of Microbiology, Academic Press."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","article-title":"New Developments in the Management of Cytomegalovirus Infection after Transplantation","volume":"78","author":"Meesing","year":"2018","journal-title":"Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1128\/AAC.02544-13","article-title":"Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Bogner, E., Egorova, A., and Makarov, V. (2021). Small Molecules\u2014Prospective Novel HCMV Inhibitors. Viruses, 13.","DOI":"10.3390\/v13030474"},{"key":"ref_77","unstructured":"Salvaggio, M.R., and Gnann, J.W. (2017). Infectious Diseases, Elsevier."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00003495-199448020-00007","article-title":"Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections","volume":"48","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in Transplant Recipients Treated with Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2016.12.003","article-title":"Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","volume":"138","author":"Chou","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_82","unstructured":"Kimberlin, D.W. (2023). Principles and Practice of Pediatric Infectious Diseases, Elsevier."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","first-page":"269","article-title":"Letermovir and inhibitors of the terminase complex: A promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/jama.2023.9100","article-title":"A New Antiviral Option for Cytomegalovirus Prevention after Kidney Transplant","volume":"330","author":"Raglow","year":"2023","journal-title":"JAMA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"204062072093715","DOI":"10.1177\/2040620720937150","article-title":"Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant","volume":"11","author":"Shigle","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: An evidence-based review","volume":"12","author":"Razonable","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e00191-22","DOI":"10.1128\/spectrum.00191-22","article-title":"Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients","volume":"10","author":"Tilloy","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e13515","DOI":"10.1111\/tid.13515","article-title":"Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature","volume":"23","author":"Hofmann","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e02405-21","DOI":"10.1128\/aac.02405-21","article-title":"New Perspectives on Antimicrobial Agents: Maribavir","volume":"66","author":"Blumberg","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for Refractory Cytomegalovirus Infections with or without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: First Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","article-title":"Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects","volume":"47","author":"Wang","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Chou, S., Alain, S., Cervera, C., Chemaly, R.F., Kotton, C.N., Lundgren, J., Papanicolaou, G.A., Pereira, M.R., Wu, J.J., and Murray, R.A. (2023). Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J. Infect. Dis., jiad293.","DOI":"10.1093\/infdis\/jiad293"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection","volume":"226","author":"Chou","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/JVI.78.2.710-715.2004","article-title":"Role of a Mutation in Human Cytomegalovirus Gene UL104 in Resistance to Benzimidazole Ribonucleosides","volume":"78","author":"Komazin","year":"2004","journal-title":"J. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.antiviral.2004.09.004","article-title":"The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs","volume":"65","author":"Schleiss","year":"2005","journal-title":"Antivir. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0166-3542(01)00127-9","article-title":"Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo","volume":"49","author":"Weber","year":"2001","journal-title":"Antivir. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/B978-0-323-02598-0.50098-7","article-title":"Retinal Disease in HIV-infected Patients","volume":"Volume 2\u20133","author":"Kosobucki","year":"2006","journal-title":"Retina"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1021\/jm00020a025","article-title":"Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles","volume":"38","author":"Townsend","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.48.5.1647-1651.2004","article-title":"Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus","volume":"48","author":"Underwood","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1128\/JVI.79.17.11115-11127.2005","article-title":"Impact of 2-Bromo-5,6-Dichloro-1-\u03b2-d-Ribofuranosyl Benzimidazole Riboside and Inhibitors of DNA, RNA, and Protein Synthesis on Human Cytomegalovirus Genome Maturation","volume":"79","author":"McVoy","year":"2005","journal-title":"J. Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/JVI.78.4.1623-1635.2004","article-title":"Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus","volume":"78","author":"Nixon","year":"2004","journal-title":"J. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Gugliesi, F., Coscia, A., Griffante, G., Galitska, G., Pasquero, S., Albano, C., and Biolatti, M. (2020). Where do we stand after decades of studying human cytomegalovirus?. Microorganisms, 8.","DOI":"10.3390\/microorganisms8050685"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/418244a","article-title":"RNA interference","volume":"418","author":"Hannon","year":"2002","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Leading Edge Review Origins and Mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1099\/vir.0.19453-0","article-title":"Inhibition of human cytomegalovirus replication by small interfering RNAs","volume":"85","author":"Wiebusch","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1128\/JVI.06338-11","article-title":"RNA Interference-Mediated Targeting of Human Cytomegalovirus Immediate-Early or Early Gene Products Inhibits Viral Replication with Differential Effects on Cellular Functions","volume":"86","author":"Xiaofei","year":"2012","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12985-020-01436-5","article-title":"Multiple gene targeting siRNAs for down regulation of Immediate Early-2 (Ie2) and DNA polymerase genes mediated inhibition of novel rat Cytomegalovirus (strain All-03)","volume":"17","author":"Balakrishnan","year":"2020","journal-title":"Virol. J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1073\/pnas.1719036115","article-title":"miRNA-mediated targeting of human cytomegalovirus reveals biological host and viral targets of IE2","volume":"115","author":"Schwarz","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","unstructured":"Skilandat, M., Zelger-Paulus, S., and Sigel, R.K.O. (2017). Reference Module in Life Sciences, Elsevier."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.coph.2010.07.002","article-title":"Therapeutic applications of ribozymes and riboswitches","volume":"10","author":"Mulhbacher","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.V91.2.371","article-title":"The Therapeutic Potential of Ribozymes","volume":"91","author":"James","year":"1998","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Lilley, D.M.J. (2019). Classification of the nucleolytic ribozymes based upon catalytic mechanism [version 1; peer review: 3 approved]. F1000Research, 8.","DOI":"10.12688\/f1000research.19324.1"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/nar\/gkh660","article-title":"RNase P ribozyme inhibits cytomegalovirus replication by blocking the expression of viral capsid proteins","volume":"32","author":"Kim","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Sun, X., Chen, W., He, L., Sheng, J., Liu, Y., Vu, G.P., Yang, Z., Li, W., Trang, P., and Wang, Y. (2017). Inhibition of human cytomegalovirus immediate early gene expression and growth by a novel RNase P ribozyme variant. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186791"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.3390\/v7072775","article-title":"RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins","volume":"7","author":"Yang","year":"2015","journal-title":"Viruses"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.2174\/092986711797189600","article-title":"Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons","volume":"18","author":"Ni","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"11902","DOI":"10.1128\/JVI.01378-09","article-title":"Inhibition of Human Cytomegalovirus Replication via Peptide Aptamers Directed against the Nonconventional Nuclear Localization Signal of the Essential Viral Replication Factor pUL84","volume":"83","author":"Kaiser","year":"2009","journal-title":"J. Virol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Mondal, D. (2016). Fomivirsen. Ref. Modul. Biomed. Sci.","DOI":"10.1016\/B978-0-12-801238-3.99403-0"},{"key":"ref_122","unstructured":"Kozak, I., Allen McCutchan, J., and Freeman, W.R. (2013). Retina, Saunders. [5th ed.]."},{"key":"ref_123","first-page":"589","article-title":"4.32 Gene Editing Tools","volume":"4","author":"Ede","year":"2017","journal-title":"Compr. Biomater. II"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.ggedit.2021.100007","article-title":"TALE and TALEN genome editing technologies","volume":"2","author":"Becker","year":"2021","journal-title":"Gene Genome Ed."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Bhardwaj, A., and Nain, V. (2021). TALENs-an indispensable tool in the era of CRISPR: A mini review. J. Genet. Eng. Biotechnol., 19.","DOI":"10.1186\/s43141-021-00225-z"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.omtn.2019.02.027","article-title":"Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application","volume":"16","author":"Khan","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: A widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Perez, E.E., Wang, J., Miller, J.C., Jouvenot, Y., Kim, K.A., Liu, O., Wang, N., Lee, G., Bartsevich, V.V., and Lee, Y.L. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol., 26.","DOI":"10.1038\/nbt1410"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e01846-22","DOI":"10.1128\/jvi.01846-22","article-title":"Strain-Dependent Restriction of Human Cytomegalovirus by Zinc Finger Antiviral Proteins","volume":"97","author":"Lista","year":"2023","journal-title":"J. Virol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Chen, S.-J., and Chen, Y.-C. (2019). Potential Application of TALENs against Murine Cytomegalovirus Latent Infections. Viruses, 11.","DOI":"10.3390\/v11050414"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","article-title":"What is CRISPR\/Cas9?","volume":"101","author":"Redman","year":"2016","journal-title":"Arch. Dis. Child.-Educ. Pract."},{"key":"ref_133","first-page":"353","article-title":"Mechanism and Applications of CRISPR\/Cas-9-Mediated Genome Editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00705-020-04687-3","article-title":"Targeting human cytomegalovirus IE genes by CRISPR\/Cas9 nuclease effectively inhibits viral replication and reactivation","volume":"165","author":"Xiao","year":"2020","journal-title":"Arch. Virol."},{"key":"ref_135","first-page":"1","article-title":"Suganthini Krishnan Using CRISPR technology to inhibit the replication of human cytomegalovirus by deletion of a gene promoter","volume":"4","author":"Natesan","year":"2021","journal-title":"J. Emerg. Investig."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.virol.2019.01.021","article-title":"Editing the human cytomegalovirus genome with the CRISPR\/Cas9 system","volume":"529","author":"King","year":"2019","journal-title":"Virology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1162342","DOI":"10.3389\/fimmu.2023.1162342","article-title":"Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: An update from the World Association of Infectious Diseases and Immunological Disorders and the It","volume":"14","author":"Esposito","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: Development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-immunol-042718-041309","article-title":"Human Antibodies for Viral Infections","volume":"40","author":"Crowe","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02467-19","article-title":"Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation","volume":"64","author":"Maertens","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1128\/JVI.79.7.4066-4079.2005","article-title":"Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B","volume":"79","author":"Britt","year":"2005","journal-title":"J. Virol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Okamoto, M., Kurino, R., Miura, R., and Takada, K. (2023). A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285672"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Parsons, A.J., Ophir, S.I., Duty, J.A., Kraus, T.A., Stein, K.R., Moran, T.M., and Tortorella, D. (2022). Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03294-z"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1093\/cid\/cit587","article-title":"Cytomegalovirus vaccines","volume":"57","author":"McVoy","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e2405","DOI":"10.1002\/rmv.2405","article-title":"Indirect effects of cytomegalovirus infection: Implications for vaccine development","volume":"33","author":"Moseley","year":"2023","journal-title":"Rev. Med. Virol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41467-023-36683-x","article-title":"The cytomegalovirus gB\/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread","volume":"14","author":"Gomes","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/infdis\/jiz447","article-title":"The Status of Vaccine Development Against the Human Cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-virology-110615-042422","article-title":"Human Cytomegalovirus Latency: Approaching the Gordian Knot","volume":"3","author":"Goodrum","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldz031","article-title":"Advances in the treatment of cytomegalovirus","volume":"131","author":"Krishna","year":"2019","journal-title":"Br. Med. Bull."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/10\/2372\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:42Z","timestamp":1760129742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/10\/2372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":150,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["microorganisms11102372"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11102372","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]}}}